Full Text:   <1280>

CLC number: R734

On-line Access: 

Received: 2005-12-23

Revision Accepted: 2006-04-17

Crosschecked: 0000-00-00

Cited: 3

Clicked: 3703

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2006 Vol.7 No.10 P.837~843

http://doi.org/10.1631/jzus.2006.B0837


Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine


Author(s):  WANG Xue-fen, TU Ling-fang, WANG Li-hong, ZHOU Jian-ying

Affiliation(s):  Department of Respirology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; more

Corresponding email(s):   wxfzy636@hotmail.com

Key Words:  TNP-470, Gemcitabine, VEGF, FLT-1, KDR


WANG Xue-fen, TU Ling-fang, WANG Li-hong, ZHOU Jian-ying. Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine[J]. Journal of Zhejiang University Science B, 2006, 7(10): 837~843.

@article{title="Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine",
author="WANG Xue-fen, TU Ling-fang, WANG Li-hong, ZHOU Jian-ying",
journal="Journal of Zhejiang University Science B",
volume="7",
number="10",
pages="837~843",
year="2006",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.2006.B0837"
}

%0 Journal Article
%T Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine
%A WANG Xue-fen
%A TU Ling-fang
%A WANG Li-hong
%A ZHOU Jian-ying
%J Journal of Zhejiang University SCIENCE B
%V 7
%N 10
%P 837~843
%@ 1673-1581
%D 2006
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2006.B0837

TY - JOUR
T1 - Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine
A1 - WANG Xue-fen
A1 - TU Ling-fang
A1 - WANG Li-hong
A1 - ZHOU Jian-ying
J0 - Journal of Zhejiang University Science B
VL - 7
IS - 10
SP - 837
EP - 843
%@ 1673-1581
Y1 - 2006
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2006.B0837


Abstract: 
Angiogenesis is required for solid tumor growth and facilitates tumor progression and metastasis. The inhibition effects of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470), an angiogenesis inhibitor, and gemcitabine, a chemotherapeutic agent, on expression of growth factors were investigated using human pulmonary adenocarcinoma cell line, A549. The A549 cells were divided into four groups: control group, 10−6 mg/ml gemcitabine treated group, 10−4 mg/ml TNP-470 treated group and gemcitabine+TNP-470 treated group. The mRNA and protein expression of vascular endothelial growth factor (VEGF) and its receptors, FMS-like tyrosine kinase-1 (FLT-1) and kinase insert domain-containing receptor (KDR), in different groups were measured. The growth of A549 cell cultured with gemcitabine or TNP-470 was inhibited in an almost dose-dependent manner. Although gemcitabine (10−6 mg/ml) alone and TNP-470 (10−4 mg/ml) alone had no effect on the mRNA and protein expression of VEGF and its receptors (FLT-1, KDR) in A549 cells compared to the control (P>0.05), 10−6 mg/ml gemcitabine in combination with 10−4 mg/ml TNP-470 had significant effect (P<0.01). Moreover, combination of the two drugs significantly inhibited the mRNA expression of VEGF, FLT-1 and KDR compared to either drug alone (P<0.05). This study suggests that combined treatment with TNP-470 plus gemcitabine may augment the antiangiogenic and antineoplastic effects in lung cancer cells in vitro.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1] Andre, T., Tournigand, C., Rosmorduc, O., Provent, S., Maindrault-Goebel, F., Avenin, D., Selle, F., Paye, F., Hannoun, L., Houry, S., et al., 2004. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann. Oncol., 15(9):1339-1343.

[2] Aprelikova, O., Pajusola, K., Partanen, J., Armstrong, E., Alitalo, R., Bailey, S.K., McMahon, J., Wasmuth, J., Huebner, K., Alitalo, K., 1992. FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter. Cancer Res., 52(3):746-748.

[3] Ferrigno, D., Buccheri, G., Cuneo Lung Cancer Study Group, 2004. Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC). Lung Cancer, 45(3):373-380.

[4] Figg, W.D., Pluda, J.M., Lush, R.M., Saville, M.W., Wyvill, K., Reed, E., Yarchoan, R., 1997. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy, 17(1):91-97.

[5] Folkman, J., 1990. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82(1):4-6.

[6] Fong, T.A., Shawver, L.K., Sun, L., Tang, C., App, H., Powell, T.J., Kim, Y.H., Schreck, R., Wang, X., Risau, W., et al., 1999. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59(1):99-106.

[7] Iwasaki, A., Kuwahara, M., Yoshinaga, Y., Shirakusa, T., 2004. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur. J. Cardiothorac. Surg., 25(3):443-448.

[8] Jia, L., Zhang, M.H., Yuan, S.Z., Huang, W.G., 2005. Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World J. Gastroenterol., 11(3):447-450.

[9] Johnson, F.M., Saigal, B., Talpaz, M., Donato, N.J., 2005. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin. Cancer Res., 11(19 Pt 1):6924-6932.

[10] Kato, T., Sato, K., Kakinuma, H., Matsuda, Y., 1994. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res., 54(19):5143-5147.

[11] Kusaka, M., Sudo, K., Matsutani, E., Kozai, Y., Marui, S., Fujita, T., Ingber, D., Folkman, J., 1994. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer, 69(2):212-216.

[12] Lacal, P.M., Ruffini, F., Pagani, E., D′Atri, S., 2005. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int. J. Oncol., 27(6):1625-1632.

[13] Lin, J., Mei, H.Z., Shi, Z.Y., Wen, G.H., 2005. Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World J. Gastroenterol., 11(3):447-450.

[14] Masood, R., Cai, J., Zheng, T., Smith, D.L., Hinton, D.R., Gill, P.S., 2001. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood, 98(6):1904-1913.

[15] Miura, S., Emoto, M., Matsuo, Y., Kawarabayashi, T., Saku, K., 2004. Carcinosarcoma-induced endothelial cells tube formation through KDR/Flk-1 is blocked by TNP-470. Cancer Lett., 203(1):45-50.

[16] Muramaki, M., Miyake, H., Hara, I., Kawabata, G., Kamidono, S., 2004. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model. J. Urol., 172(4 Pt 1):1485-1489.

[17] Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z., 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13(1):9-22.

[18] O′Reilly, M.S., 2002. The combination of antiangiogenic therapy with other modalities. Cancer J., 8(Suppl. 1): S89-99.

[19] Rifkin, D.B., Kojima, S., Abe, M., Harpel, J.G., 1993. TGF-beta: structure, function, and formation. Thromb. Haemost., 70(1):177-179.

[20] Sauter, E.R., Nesbit, M., Watson, J.C., Klein-Szanto, A., Litwin, S., Herlyn, M., 1999. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin. Cancer Res., 5(4):775-782.

[21] Senger, D.R., van de Water, L., Brown, L.F., Nagy, J.A., Yeo, K.T., Yeo, T.K., Berse, B., Jackman, R.W., Dvorak, A.M., Dvorak, H.F., 1993. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev., 12(3-4):303-324.

[22] Shibuya, M., Ito, N., Claesson-Welsh, L., 1999. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr. Top Microbiol. Immunol., 237:59-83.

[23] Shishido, T., Yasoshima, T., Denno, R., Sato, N., Hirata, K., 1996. Inhibition of liver metastasis of human gastric carcinoma by angiogenesis inhibitor TNP-470. Jpn. J. Cancer Res., 87(9):958-962.

[24] Stefanou, D., Goussia, A.C., Arkoumani, E., Agnantis, N.J., 2003. Expression of vascular endothelial growth factor and the adhesion molecule E-cadherin in non-small cell lung cancer. Anticancer Res., 23(6C):4715-4720.

[25] Storniolo, A.M., Allerheiligen, S.R., Pearce, H.L., 1997. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin. Oncol., 24(2 Suppl. 7):S7-2-S7-7.

[26] Tanaka, T., Konno, H., Matsuda, I., Nakamura, S., Baba, S., 1995. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res., 55(4):836-839.

[27] Veikkola, T., Karkkainen, M., Claesson-Welsh, L., Alitalo, K., 2000. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res., 60(2):203-212.

[28] Vieira, J.M., Santos, S.C., Espadinha, C., Correia, I., Vag, T., Casalou, C., Cavaco, B.M., Catarino, A.L., Dias, S., Leite, V., 2005. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur. J. Endocrinol., 153(5):701-709.

[29] Weidner, N., Semple, J.P., Welch, W.R., Folkman, J., 1991. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N. Engl. J. Med., 324(1):1-8.

[30] Weinstat-Saslow, D., Steeg, P.S., 1994. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J., 8(6):401-407.

[31] Yamamoto, T., Sudo, K., Fujita, T., 1994. Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res., 14(1A):1-3.

[32] Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K., Fujita, T., 1993a. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res., 53(21):5233-5236.

[33] Yamaoka, M., Yamamoto, T., Masaki, T., Ikeyama, S., Sudo, K., Fujita, T., 1993b. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Res., 53(18):4262-4267.

[34] Yanase, T., Tamura, M., Fujita, K., Kodama, S., Tanaka, K., 1993. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res., 53(11):2566-2570.

[35] Yilmaz, A., Kliche, S., Mayr-Beyrle, U., Fellbrich, G., Waltenberger, J., 2003. p38 MAPK inhibition is critically involved in VEGFR-2-mediated endothelial cell survival. Biochem. Biophys. Res. Commun., 306(3):730-736.

[36] Yukita, A., Asano, M., Okamoto, T., Mizutani, S., Suzuki, H., 2000. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Res., 20(1A):155-160.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE